Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 119 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Familial Hypercholesterolaemia Clear all

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: AAV directed hLDLR gene therapy; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions: VERVE-102, Placebo; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DeSoto, Texas

Conditions: Hypercholesterolemia
Interventions: Not listed
Lead sponsor: The Familial Hypercholesterolemia Foundation; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more

Conditions: Familial Hypercholesterolaemia
Interventions: Alert-based computerized decision support; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: Not listed
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy; Drug
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: Columbus, Ohio • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Familial Hypercholesterolemia
Interventions: Cascade Screening; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Overweight, Blood Pressure, Hypercholesteremia, Diabetes
Interventions: Motivational interviewing to elicit PCO in pediatrics; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 2 Years to 18 Years
Enrollment: 703 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
Interventions: Obicetrapib, Placebo; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more

Conditions: Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
Interventions: Motivational interview (MI); Behavioral
Lead sponsor: Essentia Health; Other
Eligibility: 2 Years to 75 Years
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Duluth, Minnesota

Conditions: Familial Hypercholesterolaemia
Interventions: rosuvastatin calcium; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Familial Hypercholesterolemia, Adherence, Medication
Interventions: Monetary incentives; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
Interventions: Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result, Adolescents who received adult-onset result, Adolescents who received a pediatric-onset result, Adolescent controls - negative for familial variant; Genetic
Lead sponsor: Geisinger Clinic; Other
Eligibility: Not listed
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012 or Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more

Conditions: Hypercholesteremia
Interventions: Gemcabene; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Hypercholesterolemia, Heterozygous Familial
Interventions: mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 20
States / cities: Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: evinacumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 5 more

Conditions: Hypercholesterolemia, Familial
Interventions: Kinetics test; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Familial Hypercholesterolemia
Interventions: 2-Hydroxybenzylamine, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Impact of LDL-cholesterol Lowering on Platelet Activation

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Study of Awareness and Detection of Familial Hypercholesterolemia

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

Equitable Implementation of Cascade Screening for Familial Hypercholesterolemia

Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence in Adolescents

Pediatric Reporting of Adult-Onset Genomic Results

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Regeneron 1331 Kinetics Sub-Study HoFH

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)